571189-10-1

Basic information

• Product Name: 4-{6-[8-CYCLOPENTYL-6-(1-ETHOXY-VINYL)-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO]-PYRIDIN-3-YL}-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-{6-[8-CYCLOPENTYL-6-(1-ETHOXY-VINYL)-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO]-PYRIDIN-3-YL}-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• CAS NO: 571189-10-1
• Molecular Formula: C₃₁H₄₁N₇O₄
• Molecular Weight: 575.70174
• Mol File: 571189-10-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-{6-[8-CYCLOPENTYL-6-(1-ETHOXY-VINYL)-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO]-PYRIDIN-3-YL}-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{6-[8-CYCLOPENTYL-6-(1-ETHOXY-VINYL)-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO]-PYRIDIN-3-YL}-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(571189-10-1)
• EPA Substance Registry System: 4-{6-[8-CYCLOPENTYL-6-(1-ETHOXY-VINYL)-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO]-PYRIDIN-3-YL}-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(571189-10-1)

Safety Data

• Hazardous Substances Data: 571189-10-1(Hazardous Substances Data)

Usage

General Description

The chemical "4-{6-[8-cyclopentyl-6-(1-ethoxy-vinyl)-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-pyridin-3-yl}-piperazine-1-carboxylic acid tert-butyl ester" is a compound that contains a piperazine ring and various functional groups, including cyclopentyl, ethoxy-vinyl, and tert-butyl ester. It also contains a pyrido[2,3-d]pyrimidin-2-ylamino group and a pyridine ring. This chemical structure suggests that it may have potential biological activity and could be used in medicinal chemistry for drug development or as a research tool for studying biological pathways. Its specific pharmacological and toxicological properties are not known, but its complex structure indicates that it may have specific interactions with biological targets.

Upstream product

• 1065075-68-4 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carboxylic acid 
• 362656-31-3 1-(4-cyclopentylamino-2-methylsulfanylpyrimidin-5-yl)ethanol 
• 571188-59-5 tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 362656-23-3 8?cyclopentyl?5?methyl?2?(methylthio)pyrido[2,3?d]pyrimidin?7(8H)?one 
• 362656-11-9 1-(4-cyclopentylamino-2-methylsulfanylpyrimidin-5-yl)ethanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 211245-63-5 [4-cyclopentylamino-2-(methylsulfanyl)pyrimidine-5-yl]methanol 
• 211245-62-4 4-cyclopentylamino-2-(methylsulfanyl)pyrimidine-5-carboxylic acid ethyl ester 
• 211245-64-6 4-cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde 
• 1003-03-8 Cyclopentamine 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 39856-50-3 5-bromo2-nitropyridine 
• 571189-16-7 4-(6-nitropyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 571190-30-2 PD 0332991 
• 827022-32-2 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride 

Relevant articles and documents

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.

CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE

The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concentrations up to 100-fold the IC50 for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.